INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 5.14
Index: ASX300 | ALL-ORDS

Integral Diagnostics is an Australian healthcare services company providing diagnostic imaging services to medical practitioners in Australia and New Zealand. It has been a listed company since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.01

25 Jun
2026

0.035

OPEN

$1.99

1.77%

HIGH

$2.03

660,326

LOW

$1.97

TARGET
$3.65

+0.15 change from previous day

 81.6% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . EBO . HLS . M7T . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 5.9 10.5 xxx
DPS (cps) xxx 9.3 7.5 xxx
EPS Growth xxx 100.0% 79.0% xxx
DPS Growth xxx 43.1% - 19.9% xxx
PE Ratio xxx N/A 16.4 xxx
Dividend Yield xxx N/A 4.3% xxx
Div Pay Ratio(%) xxx 158.2% 70.8% xxx

Dividend yield today if purchased 3 years ago: 3.51%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 5.27

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/08 - ex-div 6.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx5.9
DPS All xxxxxxxxxxxxxxx9.3
Sales/Revenue xxxxxxxxxxxxxxx788.6 M
Book Value Per Share xxxxxxxxxxxxxxx181.5
Net Operating Cash Flow xxxxxxxxxxxxxxx95.2 M
Net Profit Margin xxxxxxxxxxxxxxx2.78 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx3.20 %
Return on Invested Capital xxxxxxxxxxxxxxx1.75 %
Return on Assets xxxxxxxxxxxxxxx1.52 %
Return on Equity xxxxxxxxxxxxxxx3.20 %
Return on Total Capital xxxxxxxxxxxxxxx5.29 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx19.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx21 M
Long Term Debt xxxxxxxxxxxxxxx576 M
Total Debt xxxxxxxxxxxxxxx597 M
Goodwill - Gross xxxxxxxxxxxxxxx796 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx51 M
Price To Book Value xxxxxxxxxxxxxxx1.10

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx49.6 M
Capex % of Sales xxxxxxxxxxxxxxx6.29 %
Cost of Goods Sold xxxxxxxxxxxxxxx620 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx101 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx4 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

03/06/2026

1

Buy

$3.80

89.05%

Bell Potter notes diagnostic imaging activity strengthened in April, with rolling 12-month services growth and benefits growth improving to 3.8% and 9.1%, respectively.

MRI deregulation continues to drive utilisation growth, the analysts note, with rolling 12-month MRI benefits growth accelerating to around 14.9%.

CT activity has also improved in early 2026, which the broker believes may reflect the introduction of the national lung cancer screening program.

Integral Diagnostics is viewed as a key beneficiary, having secured around 20% of screening program volumes. Meanwhile, it's noted traditional diagnostic radiology remains in structural decline as activity continues to shift towards MRI services.

Buy rating and $3.80 target are unchanged for Integral Diagnostics.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 8.10 cents and EPS of 13.30 cents.
Bell Potter forecasts a full year FY27 dividend of 10.00 cents and EPS of 16.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

IDX STOCK CHART

FNArena News on IDX

Latest Healthcare services News

1
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
2
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
3
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals
4
Funding Overhang Weighs On Ramsay’s Rebound

Jun 10 2021 - Australia
5
Treasure Chest: More Pfizer Growth For Ebos Group

May 24 2021 - Treasure Chest
6
Treasure Chest: Demand Pumps Ramsay Health

Mar 03 2021 - Treasure Chest
7
Healius Enjoying Testing Times

Dec 11 2020 - Australia
8
The First Connection

Dec 10 2020 - Weekly Reports
9
Subdued Recovery For Ramsay Health Care

Nov 16 2020 - Australia
10
Recovery Underway For Sonic Healthcare

Jun 25 2020 - Australia